U Witzsch
Overview
Explore the profile of U Witzsch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
98
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Loch T, Witzsch U, Reis G
Urologe A
. 2021 Aug;
60(9):1125-1140.
PMID: 34351439
Ultimately, new (digital) techniques and artificial intelligence (AI) applications are changing the working environment in urology. This can be an opportunity for further development, but also a change which is...
2.
Ganzer R, Franiel T, Kollermann J, Kuru T, Baumunk D, Blana A, et al.
Urologe A
. 2017 Sep;
56(10):1335-1346.
PMID: 28856386
The target of focal therapy (FT) in prostate cancer (PC) is partial treatment of the prostate aiming at preserving surrounding anatomical structures. The intention is to minimize typical side effects...
3.
Franz T, von Hardenberg J, Blana A, Cash H, Baumunk D, Salomon G, et al.
Urologe A
. 2016 Nov;
56(2):208-216.
PMID: 27844131
Background: Several systems for MRI/TRUS fusion-guided biopsy of the prostate are commercially available. Many studies have shown superiority of fusion systems for tumor detection and diagnostic quality compared to random...
4.
Wendler J, Ganzer R, Hadaschik B, Blana A, Henkel T, Kohrmann K, et al.
World J Urol
. 2016 May;
35(1):11-20.
PMID: 27147512
Irreversible electroporation (IRE), a new tissue ablation procedure available since 2007, could meet the requirements for ideal focal therapy of prostate cancer with its postulated features, especially the absence of...
5.
Wendler J, Friebe B, Baumunk D, Blana A, Franiel T, Ganzer R, et al.
Urologe A
. 2016 Apr;
55(5):594-606.
PMID: 27119957
Background: The rising incidence of renal cell carcinoma, its more frequent early detection (stage T1a) and the increasing prevalence of chronic renal failure with higher morbidity and shorter life expectancy...
6.
Wendler J, Ganzer R, Hadaschik B, Blana A, Henkel T, Kohrmann K, et al.
Urologe A
. 2015 May;
54(6):854-62.
PMID: 26024649
Background: Irreversible electroporation (IRE), a new tissue ablation procedure available since 2007, could meet the requirements for ideal focal therapy (FT) with its postulated features, especially the absence of a...
7.
Schostak M, Kollermann J, Hadaschik B, Blana A, Ganzer R, Henkel T, et al.
Aktuelle Urol
. 2015 Feb;
46(1):39-44.
PMID: 25658230
Faced with the dilemma of choosing between the extremes of standard whole gland therapy and active surveillance, those affected by prostate cancer have recently been on the lookout for less...
8.
Baumunk D, Blana A, Ganzer R, Henkel T, Kollermann J, Roosen A, et al.
Urologe A
. 2012 Oct;
52(4):549-56.
PMID: 23073701
Introduction: Patients with low-risk prostate cancer (PCa) face the difficult decision between a potential overtreatment by one of the standard therapies and active surveillance (AS) with the potential insecurity regarding...
9.
Doehn C, Witzsch U, Siebels M
Aktuelle Urol
. 2012 Aug;
43(4):243-9.
PMID: 22869494
The incidence of renal cell carcinoma (RCC) and especially that of small RCCs is increasing. However, not all tumours are malignant and not all malignant tumours are RCCs. Although partial...
10.
Skriapas K, Hellwig W, Samarinas M, Witzsch U, Becht E
Minerva Urol Nefrol
. 2010 Jun;
62(2):151-6.
PMID: 20562795
Aim: An attractive alternative for the management of benign prostate hyperplasia (BPH) is the use of 80 W potassium titanyl phosphate (KTP). We evaluated the efficacy and safety of this...